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Background: Adjuvant endocrine therapy (AET) is prescribed to women for 5–10 years after 
treatment for estrogen receptor positive (ER+ve), early-stage breast cancer. AET has proven 
effectiveness in reducing the risk of recurrence of breast cancer and mortality. However, adher-
ence is known to be suboptimal with around 20% discontinuing by 2 years and up to 50% discon-
tinuing by 5 years. Interventions are needed to support women taking AET after breast cancer. 
The aim of this study was to develop and pilot test an e-health app for this population.
Methods: Two focus groups (n=15) and five interviews were conducted with women following 
treatment for early-stage breast cancer to assess the likely acceptability of an e-health app and 
to inform the content (Phase I). Following development of a prototype e-health app, a simple 
heuristic usability test was completed by five women in order to identify any design usability 
problems (Phase II). A further 18 women used the app for 1 month between July and August 
2016, after which they were interviewed by telephone to collect their experiences and views 
of the app (Phase III).
Results: The prototype e-health app included evidence-based information on effectiveness 
of AET, an electronic side-effects diary, a peer support forum, a repeat prescription reminder, 
suggested strategies for facilitating adherence and managing any side effects that occur, and a 
link to further evidence and useful organizations for further information and support. The app 
was received positively by women. Women found the app useful as it emphasized the impor-
tance of taking AET, helped them manage their side effects and provided details of support 
organizations, while offering empathy and exchange of suggestions for self-management 
strategies through the peer support forum.
Conclusion: Overall, findings suggest that this novel e-health app has potential as a feasible 
medium for promoting adherence to AET. Future research should evaluate the efficacy of the 
app in supporting women and promoting adherence.
Keywords: adjuvant endocrine therapy, breast cancer, e-health app, support
Plain language summary
Around eight out of ten women are diagnosed with breast cancer triggered by estrogen, and 
prescribed adjuvant endocrine therapy which blocks the estrogen in the body. This medication is 
taken for up to 10 years, but some women do not continue taking the medication for this amount 
of time, due to side effects of the drug, lack of information and lack of support.
We developed an e health app for smart phones, tablets and computers, to inform and support 
women taking AET.  The app was developed with the help of 20 women who have had early 
stage breast cancer, which informed the content of the app: information about AET, about how 
to get support, evidence of how effective AET is, an electronic side effects diary to record side 
effects, an online forum where women can chat with each other, and a prescription reminder. 
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We asked 18 women taking AET to try the app for one month, then 
give us feedback on the app.  The women were very positive about 
the app and found all the sections useful.  
The app now needs to be tested in a bigger population to find out 
whether it helps increase adherence to AET.
Introduction
Adjuvant endocrine therapies (AETs) such as tamoxifen 
and aromatase inhibitors have proven clinical benefits in 
reducing the risk of recurrence of breast cancer when taken 
for 5–10 years, transforming outcomes for women with 
estrogen receptor-positive (ER+ve) breast cancer.1 However, 
despite these recognized benefits, there is good evidence that 
adherence to AET is poor: around 20% of those prescribed 
AET have discontinued treatment by 2 years and up to 50% 
by 5 years.7,8 Non-adherence to AET, whether through poor 
compliance or treatment cessation, is associated with a two- 
to three-fold increased risk of breast cancer recurrence and 
mortality.2–6
Factors shown to contribute to sub-optimal adherence 
include significant side effects, psychological problems, 
lack of information and support, poor patient–clinician 
relationships, poor recall, and limited belief in the efficacy 
of, or concerns about the medication.7–12 With shorter hos-
pital follow-up times, a focus on more personalized treat-
ment and reduced use of chemotherapy,14 it is increasingly 
important to support women with breast cancer to adhere 
to AET, to protect against recurrence and mortality.13–15 
Innovative models of community-based follow-up care are 
therefore needed to inform, support and motivate adher-
ence to AET.
E-health interventions, including smartphone and 
other e-health technologies, have seen enormous growth 
internationally over the past decade, changing the shape of 
health care and clinical research.16 Smartphones and tablets 
have become useful tools in the practice of evidence-based 
medicine at the point of care, and increasingly play a role 
in patient education, disease self-management and remote 
monitoring of patients. Use of e-health may also help inte-
grate self-management support into aftercare for cancer 
patients.15 Support for self-management is particularly 
important for cancer survivors as health professionals have 
limited resources to provide such support and evidence 
suggests that cancer survivors want to be involved in 
health care decisions.17,18 Since patient-initiated aftercare 
is becoming more common, integrating technology-based 
self-management support into a single platform will provide 
cancer survivors with the knowledge, skills and confidence 
to manage the long-term implications of cancer treatment.19 
There are a growing number of contemporary e-health apps 
that provide educational and self-assessment tools for women 
with breast cancer, but to date no app has been developed 
specifically to educate and support women taking long-term 
AET.20–23 We aimed to explore, develop and pilot a patient-
centered e-health app to support and motivate women taking 
AET. We report here the patient-led development of the 
app (Phase I), usability of the prototype app (Phase II), and 
feasibility of the prototype app (Phase III).
Methods
A qualitative approach was adopted to inform the development 
and feasibility of a prototype app. The study was approved 
by the Oxford Brookes University Ethics committee. All 
participants gave their written informed consent prior to 
participation in the study, and it was conducted in accordance 
with the Declaration of Helsinki.
sample and recruitment
Women who had completed active treatment for early-stage 
breast cancer (1–111A), were 18 years or older and able 
to provide informed consent were eligible for the study. 
Recruitment was through the UK charity Breast Cancer 
Care’s and Independent Patient Cancer Voices’ patient 
forums and newsletters. Participants were recruited between 
January 2016 and March 2016 for the development phase 
of the study and in June and July 2016 for the pilot of the 
prototype. For the pilot phase, women participating needed 
to own a smartphone, tablet or computer.
Design and setting
Phase i: informing the development of the app
Two focus groups (n=15) and five telephone interviews were 
conducted to gain women’s perspective on the acceptability 
of using an app to provide support to women prescribed AET 
and promote adherence. Possible content of the app was also 
explored. Focus groups took place at a charity headquarters 
and cancer center in the South East of England and lasted 
up to 1 hour. Telephone interviews were conducted with 
women who wanted to participate, but were not able to 
attend the focus groups. The focus groups and interviews 
were facilitated by an experienced qualitative health care 
researcher (JB).
Following the analysis of the focus groups and the inter-
views, a prototype app was developed by an app developer, 
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informed by the data from Phase I. This was an iterative 
process over a 3-month period. Researchers, service users 
and the app developer worked collaboratively throughout 
this process. The app was an independent app, with restricted 
access for the purposes of this development phase.
Phase ii: testing the usability of the app
Five women from Phase I participated in a simple heuristic 
usability test of the app to identify any design usability 
problems.24 It has been shown by Nielsen in 199425 that 
three to five users are sufficient to uncover most usability 
problems. Usability assessments were conducted at the 
participant’s home under the supervision of the researcher 
(JB). The following tasks were performed: Task 1: down-
load the app; Task 2: navigate between the sections; Task 
3: record side effects of AET experienced in the past week 
on electronic side-effect diary reporting the severity of the 
side effects (mild, moderate or severe); Task 4: set a repeat 
prescription reminder; and Task 5: access online forum. 
These tasks were set to assess the ease of using the app to 
ensure: simplicity of the download process; ease of naviga-
tion between different sections; successful interaction on 
forum; successful use of electronic side-effects diary; and 
successful use of the prescription reminder. Women were 
given written instructions for the tasks and the talk aloud 
procedure was used to assess tasks. Women were asked to 
rate how user-friendly the app interface was. The women 
were also asked to rate their level of satisfaction regarding 
the usability of the app.
Phase iii: pilot of the app
Eighteen women prescribed AET following breast cancer 
were provided with detailed instructions of how to download 
the app either onto their smartphone, tablet or computer 
and asked to use the app on their own device for a month 
from July 21, 2016 to August 20, 2016. During that month 
support was available to participants, if required, from the 
app developer. The electronic forum was moderated by an 
experienced health researcher (JB).
Semi-structured telephone interviews were conducted 
after the 1-month trial period to explore women’s experiences 
and views of the app. Interviews lasted no longer than 
30 minutes.
Data analysis
The focus groups and interviews in both Phase I and Phase 
III were digitally recorded, transcribed verbatim with consent 
from the participants. The data were analyzed using thematic 
analysis.26 Familiarization with transcripts was followed by 
the process of systematically coding the data to generate ini-
tial codes. After initial coding, texts were iteratively analyzed 
through a cyclical inductive process. Themes were identified 
from the initial codes, further codes were identified, leading 
to further new themes or combining of themes. Transcripts 
were revisited until no more themes could be identified. 
During this process, themes were merged or added until an 
accurate representation of the data was agreed by researchers 
(JB, MB, and EW).
Results
Phase i: informing the development 
of the app
Twenty women aged 46–73 years took part in this phase. 
Fourteen were married or living with a partner, two were 
divorced, one was single, and three were widowed. Education 
level included the following: completion of secondary (n=8), 
completion of college or university (n=9), and completion 
of postgraduate (n=3).
Two main findings from Phase I were as follows: 1) 
Acceptability of the app (appropriateness of using an e app 
and practicality of using the app); and 2) Content suggestions 
(useful sections/useful information).
Acceptability of the app
Women were generally positive about the concept of an app to 
provide information and support while taking AET, and could 
see great potential for an app helping women to cope with 
some of the common issues that arise when taking AET.
I think having apps to provide information and support 
in healthcare is the way forward. It can provide specific 
information to specific treatment group in a paperless 
format – seems the sensible way […] I would use it to help 
with this hormone treatment [AET].
However, not all women in the sample had a smartphone 
or a tablet and it became clear that to be as inclusive as 
possible the app would have to be available for download on 
multiple platforms. Furthermore, women emphasized that the 
app needed to be easy to download and simple to navigate 
between the relevant sections.
It needs to be flexible – to be downloaded on different 
devices. For example, I tend to use a computer – so I would 
want to download it onto my computer at home. I know 
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I am unusual in not having a mobile phone. I expect most 
of the younger women would download it on their mobile 
phone or their tablet. It depends on the device you are used 
to using.
I think because of my age it can be scary to use these 
things. I do try though. My grandchildren help. As long as 
it is easy to use, obvious, intuitive.
content of the app
Women felt a potential benefit of an app was that it could 
provide information that was easily accessible at the time it 
was needed, and could provide different levels of informa-
tion so that women can choose the level appropriate to them. 
Women reported provision of information about AET was 
often at their initial treatment plan when primary treatment 
had been their priority. Furthermore, the level of information 
provided had not always been appropriate, with some women 
wanting detailed information of the evidence, while others 
wanted only summary information. One woman commented 
on the difficulty of getting this right:
It’s a difficult one. Some women want the full picture to 
fully understand what they are taking. Others want a black 
and white sketch, but not the details. They just want to know 
enough. Others do not want to see the picture, they just want 
to get on with it without knowing too much. Catering for 
all is a challenge.
Most women considered peer support to be important 
and reported use of online support forums run by charities. 
However, while the women found these charity forums 
supportive, some women found they increased their anxiety 
because of the spectrum of women participating, some of 
whom had advanced disease. They felt a forum specifically 
for women taking AET after early-stage breast cancer would 
be useful to discuss issues and exchange tips in managing 
the side effects. Women also spoke of wanting to exchange 
information with other women about specific brands of 
products that had helped reduce the side effect profile, which 
charities and NHS information were not able to do.
It took me a long time to find out that different brands 
have worse side effects than others. I now go to a specific 
pharmacist to collect my prescription because I know he will 
supply the good ones. This is the sort of thing you do not 
find out from the health professionals. You need to discuss 
it with other women in the same situation as you.
Women felt the side effects they experienced were not 
given much attention by health professionals, and they 
suggested an intervention where they could record side effects 
to help “legitimize” discussion of the side effects with health 
professionals. Some women recorded their side effects in a 
paper diary, not only to provide evidence of their side effects 
at clinic appointments but also to identify patterns of and plan 
around the side effect profile and identify possible triggers.
My GP wasn’t interested, so I took it upon myself to do 
something. Every day for two weeks I wrote a diary to 
record my side effects. It just helps you take control of 
the situation.
Participants also spoke of the importance of having 
advice around where to seek further information. Many had 
been overwhelmed by the amount of information provided 
on the Internet and suggested that the app provides links to 
trustworthy websites and organizations.
… there is too much out there on the Internet which is not 
always kosher and you can frighten yourself.
In the first focus group, women discussed their frustra-
tion of having to order repeat prescriptions every month and 
raised the question of including text message reminders on 
the app. However, involving a health professional to deliver 
this intervention would add an additional layer of complexity, 
and women suggested having a function where they could 
set reminders themselves instead.
… it’s quite a challenge over five years – with my GP […] 
I used to get two months at a time but not every GP is as 
cooperative.
Following the analysis of Phase I, the research team and 
app developer identified the functions for the prototype app 
(Table 1).
The prototype app was developed to include these func-
tions. Figure 1 shows the initial navigation page of the app. 
Figure 2 demonstrates the side-effects diary function.
Phase ii: usability of the app
Five women aged 51–73 years who had been prescribed AET 
after breast cancer piloted the prototype app in terms of its 
usability. Women reported that its user interface provided a 
clear display with intuitive controls. All the set tasks were 
completed successfully with all participants scoring 100%. 
Each task was completed in a timely manner, although there 
were delays in accessing the forum. User satisfaction was 
good in all tasks and few errors were recorded. Errors that 
did occur included problems downloading the app onto the 
platform chosen and contributing to the online forum.
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Table 1 Functions for the prototype app
Functions for prototype informed by Phase I
1. Evidence-based information about the treatments, side effects, and alternative AeT medication, as well as coping strategies and sources of support.
2. Links to current evidence, clinical trials and systematic reviews.
3. Electronic side-effects diary to record side effects of AeT and their severity (mild, moderate or severe) to inform clinic appointments, or 
for personal use, eg, identify triggers.
Note: common side effects include hot flushes, night sweats, anxiety, depression, joint ache, weight gain, and vaginal dryness.
4. Electronic repeat prescription reminder which women could set up to remind them to get their monthly/bi-monthly prescription.
5. Online forum for women to chat with other women taking AET, with a confidential messaging section for individual messages to specific people.
6. Information about charities and other organizations where women can seek support.
7. Links to good Internet sites and to other useful organizations.
Abbreviation: AeT, adjuvant endocrine therapy.
Figure 1 screen shot of app home page detailing the different sections.
Figure 2 screen shot of electronic side-effect diary. groups – give access to online 
forum. Alerts – give access to electronic prescription reminder. Messages – for 
confidential messages sent between women in the forum.
Phase iii: pilot of the app
Eighteen women who had been taking AET for 1–5 years 
participated in the pilot of the app. Table 2 below reports the 
sample characteristics.
The data are reported by section headings of the e-health 
app: 1) downloading and introduction; 2) side-effects diary; 
and 3) information and evidence.
Downloading and introduction
Women reported that downloading and navigating between 
sections of the app was straightforward and that the app was 
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user-friendly. Additional features suggested were a calendar, 
note-taking and audio-recording functions, a list of questions 
to ask the doctor, a glossary of terms, and links to additional 
resources.
Women found the introduction section helpful, guiding 
them through each section and providing explanations for 
how to maximize the use of each of the sections.
side-effects diary
Most women used the electronic side-effects diary to record 
and help manage side effects and could see how it could be 
used to show evidence of the extent of side effects to health 
professionals. Several women described how it gave them a 
sense of control over the side effects and being able to observe 
good days as well as the bad days felt reassuring.
Some of the women suggested additional side effects that 
had not been included in this section, such as panic attacks 
and anxiety. Three women did not use the side-effects diary 
as they felt this emphasized the side effects, drawing attention 
to them more than they felt necessary.
The problem I have is that I get to the appointment and 
they start talking about the impact of the radiotherapy 
and all the side effects of the AET slip from my mind. If I 
could regularly record my side effects I could take this and 
show them. It would prompt a conversation about AET. 
[Participant 7, 54 years]
I’m trying not to study whether I have a side effect or 
not because it might dominate and therefore it takes over 
your life. [Participant 13, 68 years]
While many women completed the side-effects diary on a 
daily basis, some felt this was not necessary as side effects did 
not change much on a daily basis. Some suggested a weekly 
side-effects diary might be more appropriate.
I did the diary most days which I found really helpful 
because that was a bit – I found that the most useful – 
I would do a diary entry most days – some of the ladies were 
saying what was the point of the diary – nothing changes 
actually some days do change for me – some are good and 
some not so it was good to keep a track – I found it quite 
reassuring as well. [Participant 9, 42 years]
information and evidence
The information section provided details of the different types 
of AETs, what side effects to expect, and coping strategies 
for side effects. Most women found this section useful and 
easy to understand and commented on how reassuring they 
found knowing that side effects were due to AET.
Some women wanted additional information about the 
specific products they could use to alleviate the side effects, 
and how they can self-manage the side effects themselves 
without reliance on visiting the GP. Having personal stories 
of how women coped with the side effects throughout their 
trajectory on the drug was suggested to make it easier to 
relate to the information provided. Women also reported 
wanting more information about estrogen effects and the 
etiology of the cancer.
One woman commented that the information did not 
add much to the information provided in the leaflets she had 
received and on the Internet.
I was surprised how comprehensive it was – the informa-
tion was good – it was easily readable – it was in everyday 
English so it was relatively easy to understand and follow. 
[Participant 9, 42 years]
It is great to have information that makes the association 
between the drug and the side effect – it’s reassuring that 
I haven’t got something more serious. [Participant 3, 
64 years]
Online forum
Women had mixed views of the usefulness of the online 
forum. Some women found the peer support comforting and 
reassuring, and thought it would be a good platform to swap 
ideas and provide advice on coping strategies.
Some women found it difficult to access the forum 
because the link to it was not on the home dashboard. Others 
said they were not brave enough to post something, while one 
woman expressed a preference to be private and not discuss 
issues on the forum.
[…] just knowing you are not alone and maybe somebody 
saying oh well this is what I do. [Participant 10, 31 years]
Table 2 characteristics of the research participants in Phase iii
Variables n
Age (years)  
31–45 2
46–60 7
61–75 9
Partner status  
Married 14
Widowed 2
single 2
Treatment  
Tamoxifen 11
Aromatase inhibitors 7
reported stage of primary cancer at diagnosis  
stage 1 8
stage 2 10
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Probably that part of the app where you can talk to other 
like-minded people on forum. [Participant 14, 57 years]
[…] my coping mechanism is to isolate myself and 
not to know anyone else’s troubles – it’s just not for me. 
[Participant 18, 74 years]
electronic prescription reminder
Women could see the potential usefulness of being reminded 
to order their next prescription through the electronic alerts 
system. They found managing the monthly prescription 
requests challenging long-term and found setting up the 
reminder easy with the alert popping up on their phone 
or tablet. Several women already had their own reminder 
systems and said in reality they would not use the reminder 
system. One woman said she would not use it because she 
already received monthly reminder texts from her chemist.
Loved it – works a treat. I got an alert on my phone. 
It was really good. In fact I […] use it for my shopping!! 
[Participant 11, 63 years]
I have a really busy life so I do forget sometimes 
[to order prescription] […] I need something like this. 
[Participant 12, 61 years]
Useful links
Women really appreciated being guided to reliable support 
organizations and Internet sites. They reported the importance 
of navigating those newly prescribed AET to trustworthy 
resources, to avoid delay in finding support. Additional 
charities to add to this section were suggested.
Yes that’s really good. There is so much on the Internet 
that you often do not know where to start. A little guidance 
at the beginning helps you find the right support for you. 
[Participant 7, 54 years]
It would have been useful to have this information 
at the beginning – I felt I found out about them too late. 
[Participant 15, 53 years]
I’m really pleased you have the Maggie, Haven and 
Penny Brohn plus the big ones such as Macmillan and 
Breast Cancer Care. [Participant 16, 67 years]
There were mixed views on providing links to the 
evidence on AET. Some women commented that it was 
important to direct women to the evidence, to ensure the 
information they are receiving is accurate, as many of the 
websites provided scary statistics. One woman, although 
she had not read the evidence provided, found having the 
section reassuring because she knew she could access it 
at any time. She had felt the health professionals had held 
back on providing too much information, so by having the 
evidence freely available she felt she had more trust in the 
efficacy of AET.
Other women reported that they did not use this section 
because it was too academic for them and difficult to 
comprehend.
[…] the weirdest thing was because it was there I felt 
relaxed – when you know there is evidence there and I 
know where to get the information – when you cannot get 
the information well there’s no studies there’s something 
wrong so it’s a weird psychological confidence thing. 
[Participant 17, 65 years]
I looked at those and thought Oh this looks very dense – 
I cannot deal with that – it’s too much – it’s not snappy – it’s 
quite academically driven. [Participant 18, 74 years]
All but one woman said she would recommend the app 
to women prescribed AET. The one woman who would not 
recommend the app to other women reported that she did not 
think it would add much to the information provided by the 
health professionals or the current Internet sites.
Discussion
This study describes the development of an app to support 
women prescribed AET after breast cancer. Greater support 
and information around AET may help improve adher-
ence, thus reducing the risk of recurrence and breast cancer 
mortality. An informative and supportive e-health app 
could facilitate this. The prototype of the app developed 
provided: evidence-based information about the different 
types of AETs, and the possible side effects alongside sug-
gested coping strategies; an electronic side-effects diary to 
record evidence of side effects, improve awareness of side 
effects and to allow women to consider ways of managing 
the side effects; an online forum for support and exchange 
of suggestions of self-management; a self-setting electronic 
repeat prescription reminder; links to evidence of trials 
and systematic reviews on AET; and links to other use-
ful organizations and Internet sites to gain further support 
and information. The app was positively received by most 
women in the pilot phase of the study, and suggestions were 
made to improve the individual sections. For a few women, 
the app would not be useful, preferring either paper copies 
of booklets or face-to-face discussions with health profes-
sionals and peers.
E-health resources are increasingly being used as a 
resource for support and information by cancer survivors.27,28 
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Previous studies have found that cancer-focused apps have 
the potential to enhance efforts to promote behavior change, 
to monitor a host of symptoms and physiological indicators 
of disease, and to provide real-time supportive interventions, 
conveniently and at low cost.29 Such interventions can 
provide an efficient method of providing specific support 
and information to the unique needs of a cancer group all 
on one platform.30–32 Recent studies have found that the apps 
successfully improve activity and quality of life33–35 and 
weight reduction36 in breast cancer survivors, but no studies 
have reported on an app specifically aimed at educating and 
supporting women prescribed AET despite evidence of the 
need for support intervention.7–12
Apps have been used successfully to improve adherence 
to medication.37,38 E-health interventions such as apps 
provide several advantages of paper information and leaflets. 
Access to the information can be quicker and it is easier to 
keep information accurate and updated. Furthermore, the 
additional interactive modes such as the online forums act 
as an electronic bulletin board that are always available 
so that individuals can exchange information and mutual 
support while maintaining anonymity to users. Adherence 
apps are inexpensive, scalable, and accessible to anyone 
with smartphone, tablet or computer. The disadvantage of 
e-health interventions is the lack of access for those with low 
incomes, older people, and rural communities who may not 
have these e-health platforms.
This study provides original data on patients’ views and 
experiences of using an innovative technology to support 
women prescribed AET after breast cancer. The study was 
a pragmatic and “real-life” exploration of the use of this 
technology in a realistic setting using a convenience sample. 
The participants used the app on their personal mobile 
phones, tablets or computers, making it a low cost resource. 
Further research is needed to develop and evaluate the app 
further. While the interface of the app was clear to women, 
the next version of the prototype could incorporate colorful 
icons to make it more user-friendly. Limited funds prevented 
the development of a more technically advanced e-health app 
for women after treatment for breast cancer.
Conclusion
This study describes the development and pilot of a 
novel patient-centered e-health app that was developed in 
collaboration with breast cancer patients to provide information 
and support for women taking AET. Further development and 
evaluation of the app are needed to determine whether the app 
supports women and improves adherence to AET following 
treatment for early-stage breast cancer.
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